SCIOTEQ
15.2.2024 12:01:28 CET | Business Wire | Press release
ScioTeq, a leading provider of mission-critical defense and avionics visualization and computing solutions, announces the establishment in Bangalore, India of ScioTeq Pvt Ltd, a wholly owned subsidiary of ScioTeq bv. This move will further extend ScioTeq’s global presence by providing Sales, Procurement and Services at its Bangalore location. Additionally, by joining with local partners it will position ScioTeq to support local trade sales and manufacturing of its products and solutions for the Defense market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215830655/en/
ScioTeq Group Worldwide Locations. (Photo: Business Wire)
This move aligns with the “Make in India” initiative of the Government of India to create and encourage companies to develop, manufacture and assemble products made in India and incentivize dedicated investments into manufacturing. The policy creates a conducive environment for business investment, while building a modern structure and opening new sectors for capital investment. It also creates additional jobs that align with the government’s mantra “Atmanirbhar Bharat” (Self Reliant India) which is focused on promoting indigenization in the Defense sector.
“ScioTeq is excited to evolve our long-term relationship with India’s defense community to the next level with this newly established subsidiary,” said ScioTeq Vice President of Defense & Security, Klaas Peerlinck. “It confirms our commitment as a partner in India’s defense manufacturing establishment as well as providing a base to provide dedicated service and sales needs.”
India’s Defense budget is the fourth largest in the world thus providing various opportunities for Defense industries to engage and partner with them as they develop and upgrade their military capabilities. ScioTeq, the largest independent advanced visualization company globally, has engaged with the Indian defense establishment for over two decades, providing critical visualization solutions. This long-term experience in the country, robust portfolio of visualization and computing displays and now a local base of operations, amply positions ScioTeq for future growth and provides the Indian Defense sector with visualization and computing solutions across all three of its services - the Navy, Army, and Air Force.
“We welcome the move by ScioTeq in incorporating a wholly owned subsidiary in India to drive indigenous manufacturing of their products. We value our association and look forward to working with them,” said Mr. Arun Ramchandani, Head of Larsen & Toubro Defence (L&T). L&T is a multinational Indian conglomerate engaged in various industry sectors including defense.
About ScioTeq
ScioTeq has 35+ years’ experience designing, engineering and manufacturing high-tech, innovative, life- and mission-critical computing & visualization solutions for the Air Traffic Control, Avionics and Defense & Security markets. With headquarters in Belgium and five additional locations worldwide, they are a trusted partner in advanced computing & visualization solutions. ScioTeq products are used in the air, on the ground and at sea, delivering mission-critical information to operators on some of the most advanced platforms on the planet and in some of the most challenging environments.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215830655/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 09:00:00 CET | Press release
Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi
Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 07:00:00 CET | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare
HJS Foundation Releases JEP Protocol & HJS Framework: The "Black Box" for AI, Enabling Verifiable Human Oversight24.3.2026 04:36:00 CET | Press release
HJS Foundation (Human Judgment Systems Foundation) today released two complementary solutions: the Judgment Event Protocol (JEP) and the Human Judgment Structure (HJS) framework. As a minimalist open standard, JEP generates tamper-proof records of AI decision accountability, just like an aircraft black box; HJS embeds human judgment logic into AI operation processes — together, they transform "human oversight" from a regulatory requirement into a verifiable technical fact, providing an optional technical solution for AI accountability. How to prove that AI decisions (such as loan approvals, medical diagnoses, border screenings, etc.) have undergone human review? JEP generates immutable audit trails of human intervention through four cryptographic primitives — Judge, Verify, Delegate, Terminate; HJS builds a controllable and accountable system to prevent risks such as AI drift and ensure that human judgment guides AI operations. Current systems rely on alterable post-hoc documentation,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom